



Amal Therapeutics Wins 2d prize 2016 at Global Healthcare Innovation Academy (GHIA), Calgary

Amongst several applications within the four partner sites, 14 candidates have been shortlisted for the 2016 Global Healthcare Innovation Academy in Calgary. Amal Therapeutics represented by Jean-François Mayol, was selected in the top 6 innovations by the Grand Jury comprised of international and local experts in science, innovation, healthcare, business, IP and marketing.

Amal Therapeutics earned the 2d Award of Excellence and a CAD-15'000 prize.

About GHIA

The Global Healthcare Innovation Academy is a partnership event consisting of the following member organizations: W21C, University of Calgary, Geneva University Hospitals and Faculty of Medicine, School of Nursing, Hong Kong Polytechnic University and St. Michael's Hospital Toronto. The overarching goal of this combined scientific and business pitch competition is to provide a platform that allows entrepreneurs and healthcare professionals at any level with the encouragement and incentive to identify, nurture, and pioneer innovations in the health system.

www.ghiaevent.com, ghiaevent@gmail.com

About Amal Therapeutics

Amal Therapeutics SA is a privately held Swiss biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics uses its proprietary technology platform KISIMA to develop and progress therapeutic vaccines in oncology.

www.amaltherapeutics.com, contact@amaltherapeutics.com